These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31294133)

  • 21. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
    Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
    BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test.
    Hutson PR; Oettel K; Douglas J; Ritter M; Messing E; Staab MJ; Alberti D; Horvath D; Wilding G
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):373-7. PubMed ID: 17922273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients With Metastatic Prostate Cancer: A Societal Perspective.
    Rezaee M; Karimzadeh I; Hashemi-Meshkini A; Zeighami S; Bazyar M; Lotfi F; Keshavarz K
    Value Health Reg Issues; 2024 Jul; 42():100982. PubMed ID: 38663058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.
    Chen N; Wang Z; Chen M; Ma Q; He Y; Wang Y; Li X; Qiu M; Shi L; Zhu S; Xie Q; Liu X; Shi B; Lin G; Yang W; Liao Y; Zhang H; Wang S; Li J; Wang S; Dong L; Chen H; Lu J; Cheng Y; Zhang X; Ma L; Zhou L; Wang H; Li S; Ye D
    Cancer Biol Med; 2024 Feb; 20(12):1047-59. PubMed ID: 38318809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.
    Yri OE; Bjoro T; Fossa SD
    Eur Urol; 2006 Jan; 49(1):54-8; discussion 58. PubMed ID: 16314038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
    Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
    Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.
    Wilke D; Patil N; Hollenhorst H; Bowes D; Rutledge R; Ago C
    Pharmacotherapy; 2018 Mar; 38(3):327-333. PubMed ID: 29337395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
    Gu C; Wang Z; Lin T; Liu Z; Han W; Zhang X; Liang C; Liu H; Yu Y; Xu Z; Liu S; Wang J; Jia L; Yao X; Liao W; Fu C; Tan Z; He G; Zhu G; Fan R; Yang W; Chen X; Liu Z; Zhong L; Shi B; Ding D; Chen S; Wei J; Yao X; Chen M; Lu Z; Xie Q; Hu Z; Wang Y; Guo H; Fan T; Liang Z; Chen P; Wang W; Xu T; Li C; Xing J; Liao H; He D; Wu Z; Yu J; Feng Z; Yang M; Dou Q; Zeng Q; Li Y; Gou X; Zhou G; Wang X; Zhu R; Zhang Z; Zhang B; Tan W; Qu X; Sun H; Gan T; Ye D
    Chin Med J (Engl); 2023 May; 136(10):1207-1215. PubMed ID: 37010251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
    Iannazzo S; Pradelli L; Carsi M; Perachino M
    Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F; Candas B; Gomez JL; Cusan L
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
    Gulley JL; Figg WD; Steinberg SM; Carter J; Sartor O; Higano CS; Petrylak DP; Chatta G; Hussain MH; Dahut WL
    J Urol; 2005 May; 173(5):1567-71. PubMed ID: 15821487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    Perachino M; Cavalli V; Bravi F
    BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
    Merseburger AS; Hupe MC
    Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
    van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
    Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer.
    Ishizuka O; Nishizawa O; Nishizawa S; Satoh T; Wajiki M; Kiyokawa H; Inoue Y; Kobayashi S; Mizusawa H; Nakagawa T
    Int J Clin Oncol; 2013 Jun; 18(3):524-30. PubMed ID: 22552359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer.
    Kuhn JM; Abourachid H; Brucher P; Doutres JC; Fretin J; Jaupitre A; Jorest R; Lambert D; Petit J; Pin J; Blumberg J; Dufour-Esquerré F
    Eur Urol; 1997; 32(4):397-403. PubMed ID: 9412795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.